Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Summary

This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of intercalated combination of doublet chemotherapy of paclitaxel plus carboplatin and erlotinib on patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation.

Timeline

Start

2014-03

Primary completion

2017-01-20

Completion

2017-01-20

Outcome

Outcome not reported

Stopped (Enrollment): “Because of the very slow enrollment, this study was stopped.”

Drugs

Indications